Evidence map›Paper›PMID 28234212›Full record

ReviewJournal of psychiatry & neuroscience : JPN2017

Antidepressant effects of ketamine and the roles of AMPA glutamate receptors and other mechanisms beyond NMDA receptor antagonism.

Lily R Aleksandrova, Anthony G Phillips, Yu Tian Wang

Open access · bronzeAbstract readReview
In one paragraph

Review in Journal of psychiatry & neuroscience : JPN, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 109 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
109citing papers in PubMed, 4 pooled it
13.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

109 citing papers in PubMed, 4 syntheses or guidelines pooled it, 221 citations in OpenAlex.

  1. Is the antidepressant efficacy of ketamine and esketamine mediated via opioid mechanisms?European psychiatry : the journal of the Association of European Psychiatrists · 2026
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Review
  7. Ketamine and Evolving Neuroplasticity.Clinical drug investigation · 2026
    Review
  8. Psychedelics in treatment-resistant depression: a comprehensive review of mechanisms, clinical evidence, and recommendations.Neuropsychiatrie : Klinik, Diagnostik, Therapie und Rehabilitation : Organ der Gesellschaft Osterreichischer Nervenarzte und Psychiater · 2026
    Review
  9. Psychedelics in treatment-resistant depression: a comprehensive review of mechanisms, clinical evidence, and recommendations.Neuropsychiatrie : Klinik, Diagnostik, Therapie und Rehabilitation : Organ der Gesellschaft Osterreichischer Nervenarzte und Psychiater · 2026
    Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. American ginseng (Journal of ginseng research · 2026
    Article
  15. Article
  16. Article
  17. Ketamine Reverses Chronic Stress-Induced Behavioral Changes via the Expression of CaFASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025
    Article
  18. Article
  19. Review
  20. First-in-Human Study ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025
    Article

49 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Lily R AleksandrovaFrom the Djavad Mowafaghian Centre for Brain Health, University of British Columbia, Vancouver, BC, Canada (Aleksandrova, Wang); and the Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada (Aleksandrova, Phillips).
Anthony G PhillipsFrom the Djavad Mowafaghian Centre for Brain Health, University of British Columbia, Vancouver, BC, Canada (Aleksandrova, Wang); and the Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada (Aleksandrova, Phillips).
Yu Tian WangFrom the Djavad Mowafaghian Centre for Brain Health, University of British Columbia, Vancouver, BC, Canada (Aleksandrova, Wang); and the Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada (Aleksandrova, Phillips).
University of British Columbia · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The molecular mechanisms underlying major depressive disorder remain poorly understood, and current antidepressant treatments have many shortcomings. The recent discovery that a single intravenous infusion of ketamine at a subanesthetic dose had robust, rapid and sustained antidepressant effects in individuals with treatment-resistant depression inspired tremendous interest in investigating the molecular mechanisms mediating ketamine's clinical efficacy as well as increased efforts to identify new targets for antidepressant action. We review the clinical utility of ketamine and recent insights into its mechanism of action as an antidepressant, including the roles of

Indexed as

AnimalsAntidepressive AgentsDepressionHumansKetamineModels, NeurologicalReceptors, AMPAReceptors, N-Methyl-D-AspartateSignal TransductionAntidepressive AgentsKetamineReceptors, AMPAReceptors, N-Methyl-D-Aspartate

Identifiers

PMID28234212
PMCPMC5487269
OpenAlexW2628731659

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.